MARKET

AIKI

AIKI

AIkido Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5204
+0.0157
+3.11%
Opening 14:51 01/20 EST
OPEN
0.5200
PREV CLOSE
0.5047
HIGH
0.5350
LOW
0.5101
VOLUME
935.84K
TURNOVER
--
52 WEEK HIGH
2.550
52 WEEK LOW
0.4901
MARKET CAP
46.67M
P/E (TTM)
-7.2278
1D
5D
1M
3M
1Y
5Y
AIkido Pharma Announces Dr. Rachel Yehuda's Appearance on CBS News
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Dr. Rachel Yehuda appeared on CBS News discussing the results of a recent FDA-approved trial using a psychedelic drug. CBS News national security correspondent David Martin ...
PR Newswire · 01/05 15:00
AIkido Pharma Offers Status Update On Its Expansion Of Key Patent Applications Into Several Major Ex-US Territories Worldwide
AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today provided a status update on its expansion of key patent applications into several major ex-US territories worldwide. For the
Benzinga · 12/14/2021 15:01
AIkido Pharma Reports Filing for Expanded Worldwide Patent Coverage on Key Assets
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a status update on its expansion of key patent applications into several major ex-US territories worldwide.
PR Newswire · 12/14/2021 15:00
We're Hopeful That AIkido Pharma (NASDAQ:AIKI) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 12/02/2021 09:24
AIkido Pharma EPS beats by $0.03
AIkido Pharma (NASDAQ:AIKI): Q3 GAAP EPS of $0.00 beats by $0.03. Cash and cash equivalents $5.95M Press Release
Seekingalpha · 11/11/2021 21:18
AIkido Pharma Reports Cash, Cash Investments $104M+ For Q3, Provides Updates On Other Highlights From Last Qtr.
AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced its third quarter ending September 30, 2021, financial highlights and provided a corporate update. Highlights Cash
Benzinga · 11/11/2021 15:02
AIkido Pharma Announces Third Quarter Highlights and Corporate Update
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced its third quarter ending September 30, 2021, financial highlights and provided a corporate update.
PR Newswire · 11/11/2021 15:00
28 Stocks Moving In Monday's Mid-Day Session
Gainers
Benzinga · 10/11/2021 16:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AIKI. Analyze the recent business situations of AIkido Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AIKI stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.
High2.000
Average2.000
Low2.000
Current 0.5204
EPS
Actual
Estimate
-0.05-0.04-0.02-0.00
Q4 2020
Q1 2021
Q2 2021
    0
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 28
Institutional Holdings: 7.70M
% Owned: 8.59%
Shares Outstanding: 89.68M
TypeInstitutionsShares
Increased
5
120.68K
New
4
79.91K
Decreased
5
712.64K
Sold Out
8
1.05M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+0.24%
Key Executives
Non-Executive Chairman/Independent Director
Robert Vander Zanden
Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer/Director
Anthony Hayes
Director
Robert Dudley
Director
Paul LeMire
Director
Kyle Wool
Independent Director
Gregory Blattner
Independent Director
Tim Ledwick
No Data
About AIKI
AIkido Pharma Inc. is a biotechnology company. It is focused on developing a diverse portfolio of small-molecule anti-cancer therapeutics. Its pipeline consists of patented technology from universities and researchers. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is focused on the treatment of three different cancers and multiple types of viral infections. It is also developing a spectrum of antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), Ebolavirus and Marburg virus. Its subsidiaries include Nuta Technology Corp., Spherix Portfolio Acquisition II, Inc., Guidance IP, LLC, Directional IP, LLC, Spherix Management Services, LLC (SMS), Spherix Delaware Merger Sub Inc., Spherix Merger Subsidiary, Inc and NNPT, LLC.

Webull offers kinds of Aikido Pharma Inc stock information, including NASDAQ:AIKI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIKI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIKI stock methods without spending real money on the virtual paper trading platform.